Geneva, April 27 -- International Clinical Trials Registry received information related to the study (NCT07535567) titled 'Postoperative Radiotherapy With Nimotuzumab ± Benmelstobart in Intermediate-Risk Head and Neck Squamous Cell Carcinoma: A Randomized Controlled Trial' on April 10.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Condition:
Head and Neck Squamous Cell Carcinoma
Intervention:
Drug: Nimotuzumab
Drug: Nimotuzumab, Benmelstobart
Recruitment Status: Not recruiting
Phase: Phase 2/Phase 3
Date of First E...